Paper Details

  1. Home
  2. Paper Details

Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours.

Author: BaileyChristopher, BirkettJoseph, De GrèveJacques, De VosFilip Y F L, DeanEmma, DirixLuc, GoesslCarsten, Grundtvig-SørensenPeter, ItalianoAntoine, JerusalemGuy, LearoydMaria, LeunenKarin, MolifeL Rhoda, PlummerRuth, RolfoChristian, RotteySylvie, SpencerStuart, SpicerJames, VerheulHenk M

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This phase I study investigated the safety and pharmacokinetic profiles of olaparib, a PARP inhibitor, in combination with different endocrine therapies (tamoxifen, anastrozole, or letrozole) for treating patients with advanced solid tumors. The study aimed to assess the safety and drug levels in the body when these medications were combined.
Paper Details　
Original Abstract of the Article :
The PARP inhibitor olaparib is efficacious as monotherapy and has potential application in combination with endocrine therapy for the treatment of breast cancer. This phase I study assessed the safety and pharmacokinetic (PK) profiles of olaparib combined with tamoxifen, anastrozole or letrozole in ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s12325-018-0804-z

データ提供：米国国立医学図書館（NLM）

Olaparib and Endocrine Therapy: A Journey Towards Personalized Cancer Treatment

The treatment of cancer is a complex and ever-evolving field, much like a desert landscape that constantly shifts and changes. Researchers are constantly seeking new and innovative approaches to combat this disease. This phase I study investigates the safety and pharmacokinetic profiles of olaparib, a PARP inhibitor, when combined with endocrine therapy for the treatment of breast cancer.

Olaparib and Endocrine Therapy: A Potential New Combination

The study explores the potential of combining olaparib with endocrine therapies, such as tamoxifen, anastrozole, or letrozole, to treat breast cancer. This combination therapy aims to target different pathways involved in cancer development, potentially leading to more effective treatment outcomes. Think of it as a camel caravan utilizing different routes to reach the same destination, with each route offering unique strengths and advantages.

A Step Towards Personalized Cancer Treatment

This research is a step toward personalized cancer treatment, where therapies are tailored to the specific needs of each patient. By understanding the interactions between different drugs, researchers can develop more effective and individualized treatment regimens. This is like having a map that guides the camel caravan through the desert, helping to navigate the complex landscape of cancer treatment and identify the most effective route for each patient.

Dr.Camel's Conclusion

This phase I study provides valuable information about the safety and pharmacokinetic profiles of olaparib when combined with endocrine therapy. The findings offer hope for developing more personalized and effective treatment regimens for breast cancer. This research is like finding a hidden spring in the desert, a source of potential for a better future in the fight against this challenging disease.

Date :
  1. Date Completed 2019-09-26
  2. Date Revised 2019-09-26
Further Info :

Pubmed ID

30324586

DOI: Digital Object Identifier

10.1007/s12325-018-0804-z

Related Literature

Article Analysis
・Effects of olaparib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.